|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant human interferon beta|
|Storage buffer||whole serum diluted in PBS|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Neutralization (Neu)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Specificity: Neutralizes human interferon beta.
Activity: 2.8x10^5 NU/ml. Interferon was titrated with the use of the cytopathic effect inhibition assay using A549 cells with EMCV, where 1 unit/ml of interferon was necessary to produce an endpoint of 50%. One neutralization unit is defined as the amount of serum required to neutralize one unit of human IFN beta to an endpoint of 50%.
Store at -20°C for short-term use (less than 6 months). For long-term storage, aliquot and store at -70°C or below for retention of full activity. Refreezing should be done on dry ice or in a dry ice/alcohol bath. Further dilution of the product should be in buffers containing protein such as 0.1% BSA.
Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response and can also inhibit the development of tumors. IFN-beta binding by its receptor results in the activation of the tyrosine kinases Jak1 and Tyk2 and phosphorylation of members of the STAT family of transcription factors, leading to the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.